International private equity firm, Cinven, has completed its previously announced sale of an indirect minority stake in SYNLAB, a leader in medical diagnostic services and specialty testing in Europe, to strategic investor Labcorp. Labcorp is a global leader of innovative and comprehensive laboratory services headquartered in the United States. Labcorp acquired the indirect minority stake through an intermediate holding company established to hold the investment with SYNLAB and is represented on the holding company board along with Cinven and the other co-investors.
SYNLAB offers a full range of innovative and reliable medical diagnostic services to patients, practising doctors, hospitals and clinics, governments and corporates. Operating in over 30 countries across four continents with more than 26,000 employees, including over 2,000 medical experts, SYNLAB performed approximately 600 million laboratory tests and achieved revenues of around €2.62 billion in 2024.
The companies plan to explore possible opportunities in the future to bring Labcorp’s innovative specialty tests to markets in Europe, consider possible procurement collaborations, evaluate opportunities to support advances in clinical trials and enrolment and improve personalised care.
